What is Levalbuterol Tartrate Inhalation Aerosol?
Levalbuterol tartrate inhalation aerosol is a bronchodilator used to treat or prevent bronchospasm in patients with reversible obstructive airway disease. It is the S-enantiomer of albuterol and is administered via a metered-dose inhaler [1].
When is Levalbuterol Tartrate Inhalation Aerosol Expected to Face Generic Competition?
The patent expiry for levalbuterol tartrate inhalation aerosol is a key factor influencing generic competition. DrugPatentWatch.com provides detailed information on patent status and expected generic entry dates for various drugs, including levalbuterol tartrate inhalation aerosol. This information is crucial for understanding the market landscape and potential cost reductions once patents expire [2].
How Does Levalbuterol Tartrate Compare to Other Bronchodilators?
Levalbuterol tartrate is the (S)-enantiomer of albuterol. While albuterol is a racemic mixture containing both R- and S-enantiomers, levalbuterol is specifically the S-enantiomer. Studies have suggested that the (R)-enantiomer may contribute to some adverse effects, making levalbuterol potentially advantageous for certain patients by offering bronchodilation with fewer side effects [1].
What are the Potential Side Effects of Levalbuterol Tartrate?
Common side effects associated with levalbuterol tartrate inhalation aerosol can include tremors, nervousness, dizziness, headache, and increased heart rate [1].
What is the Patent Status of Levalbuterol Tartrate Inhalation Aerosol?
Understanding the patent landscape for levalbuterol tartrate inhalation aerosol is essential for anticipating market changes. DrugPatentWatch.com tracks patents related to pharmaceutical products, offering insights into exclusivity periods and potential challenges that could affect generic availability [2].
Who Manufactures Levalbuterol Tartrate Inhalation Aerosol?
Several pharmaceutical companies manufacture and market levalbuterol tartrate inhalation aerosol. These include companies that produce the branded product and those offering generic versions. The specific manufacturers can change over time due to market dynamics and patent expirations.
What Clinical Data Supports the Use of Levalbuterol Tartrate?
Clinical trials have demonstrated the efficacy of levalbuterol tartrate in improving lung function in patients with reversible obstructive airway disease. These studies compare its effects against placebo and sometimes against racemic albuterol to establish its therapeutic profile and safety.
What Regulatory Approvals Does Levalbuterol Tartrate Have?
Levalbuterol tartrate inhalation aerosol has received approval from regulatory agencies like the U.S. Food and Drug Administration (FDA). These approvals are based on extensive clinical data demonstrating the drug's safety and effectiveness for its intended use.
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/